GSK plc (GSK) · 종목 정보

Benzinga · 2026. 7. 29.

GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026

https://www.gsk.com/en-gb/media/press-releases/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-living-with-hiv-as-viiv-healthcare-highlights-new-long-acting-injectable-data-at-a…

원문 보기 ↗ Benzinga

SeekingAlpha · 2026. 7. 29.

GSK plc (GSK) Q2 2026 Earnings Call Transcript

GSK plc (GSK) Q2 2026 Earnings Call July 28, 2026 9:00 AM EDTCompany ParticipantsLuke Miels - CEO & DirectorNina Mojas - President of Global Product...

원문 보기 ↗ SeekingAlpha

Benzinga · 2026. 7. 28.

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.

원문 보기 ↗ Benzinga

SeekingAlpha · 2026. 7. 28.

GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)

GSK Q2/H1 2026 results beat guidance, but valuation (forward P/E) and dividend yield weaken the Buy case.

원문 보기 ↗ SeekingAlpha

Benzinga · 2026. 7. 28.

GSK Investing £400M To Establish New R&D Center In Cambridge, U.K.

https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/

원문 보기 ↗ Benzinga

Benzinga · 2026. 7. 28.

Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.

원문 보기 ↗ Benzinga

SeekingAlpha · 2026. 7. 28.

GSK plc 2026 Q2 - Results - Earnings Call Presentation

2026-07-28. The following slide deck was published by GSK plc in conjunction with their 2026 Q2 earnings call.

원문 보기 ↗ SeekingAlpha

Benzinga · 2026. 7. 28.

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

In times of market turbulence, dividend-yielding stocks are popular for investors. Check out analyst ratings for high-yielding stocks and recent news on Bristol-Myers Squibb, GSK, and Medtronic PLC on…

원문 보기 ↗ Benzinga

Benzinga · 2026. 7. 28.

GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

GSK (NYSE:GSK) FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

원문 보기 ↗ Benzinga

Benzinga · 2026. 7. 28.

GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est

GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.690 billion estima…

원문 보기 ↗ Benzinga

Benzinga · 2026. 7. 28.

GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate

GSK (NYSE:GSK) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.27 by 6.3 percent. This is a 8.87 percent increase over earnings of $1.24 per share from t…

원문 보기 ↗ Benzinga

Benzinga · 2026. 7. 28.

GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma

Results add to a growing body of positive late-stage evidence for Ris-Rez, including recent pivotal data in advanced or relapsed small-cell lung cancerGSK is advancing development of Ris-Rez outside C…

원문 보기 ↗ Benzinga

GSK plc

GSK plc를 보는 글로벌 시선

재무 요약

관련 뉴스

GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026

GSK plc (GSK) Q2 2026 Earnings Call Transcript

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)

GSK Investing £400M To Establish New R&D Center In Cambridge, U.K.

Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday

GSK plc 2026 Q2 - Results - Earnings Call Presentation

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est

GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate

GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma

관련 제품

내 성향 트레이더로 도전

GSK plc

재무 요약

관련 뉴스

GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026

GSK plc (GSK) Q2 2026 Earnings Call Transcript

GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals

GSK: Healthy Results, But Limited Stock Upside (Rating Downgrade)

GSK Investing £400M To Establish New R&D Center In Cambridge, U.K.

Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday

GSK plc 2026 Q2 - Results - Earnings Call Presentation

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

GSK FY2031 Revenue expected to be more than $53.204B vs $45.690B Est

GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est

GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate

GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma

관련 제품

내 성향 트레이더로 도전

트레이더 성향 설정